Nuvectis Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
NVCT Nasdaq 8731 https://nuvectis.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuvectis Pharma Inc

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans? - Apr 17th, 2024 10:53 am
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines - Apr 8th, 2024 12:30 pm
5 Healthcare Stocks to Buy for 2024 - Apr 2nd, 2024 8:30 pm
Insider Buys Additional US$51k In Nuvectis Pharma Stock - Mar 21st, 2024 10:08 am
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting - Mar 19th, 2024 12:00 pm
Nuvectis Pharma to Present at the 36th Annual Roth Conference - Mar 15th, 2024 12:00 pm
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer - Mar 14th, 2024 1:00 pm
Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress - Mar 5th, 2024 1:31 pm
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights - Mar 5th, 2024 1:00 pm
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership - Feb 19th, 2024 12:31 pm
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences - Feb 9th, 2024 1:32 pm
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences - Feb 9th, 2024 1:00 pm
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2024 1:00 pm
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma - Dec 18th, 2023 1:00 pm
Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings - Nov 25th, 2023 12:40 pm
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights - Nov 8th, 2023 1:00 pm
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer - Oct 24th, 2023 12:00 pm
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully - Oct 16th, 2023 5:55 pm
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT) - Oct 16th, 2023 1:35 pm
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation - Sep 25th, 2023 11:30 pm